05. 06. 2022

Phesi global analysis of 2.5 million patients finds participants in breast cancer clinical trials are getting younger

New analysis from Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, has found that since 2014 the number of women younger than 60 years of age participating in breast cancer clinical trials has increased dramatically, with an overall increase in trial participants younger than 60 years of age from 30% to about 80% (Figure 1). The results emerge following a global analysis of 2,511,046 breast cancer patients from 4,674 investigator sites.

Read more
03. 21. 2022

New Phesi data highlights potential long-lasting impact from war in Ukraine on global clinical development

New global data analysis from Phesi shows that as of March 16, 2022, there were 65,593 recruiting investigator sites globally in this category. Of these, 2,911 (4.4%) sites were based in Ukraine and Russia (fig.1), with the majority of pharmaceutical trials currently in Phase III. A further 1,738 (2.6%) sites in neighboring Poland are also now at elevated risk as the war continues.

Read more
02. 03. 2022

Only 14% of breast cancer trials reached optimal enrolment targets in 2021, despite being the most studied indication globally

Despite being the most studied indication globally in 2021, only 14% of breast cancer trials reached optimal enrolment targets according to analysis by Phesi, provider of patient-centric analytics. The data emerges following a major global study of all clinical trials conducted in 2021, including more than 25,000 investigator sites running breast cancer trials. The Phesi model predicts that this trend will continue in 2022.

Read more
01. 14. 2022

New Phesi global analysis shows breast cancer was the most extensively studied disease area in 2021

Phesi Inc., a data-driven provider of AI-powered clinical development analytics and solutions, has today released the results of its global analysis of all clinical trials conducted in 2021. The data show that breast cancer was the most studied disease area, followed by COVID-19. Overall, oncology dominated the top five, which also included non-small cell lung cancer, solid tumors and multiple myeloma

Read more